Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK150 in Advanced Malignant Solid Tumors
NCT07566247Phase 1Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- Apr 2026
- Primary completion
- Feb 2029
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AK150 in advanced malignant solid tumor, sponsored by Akeso, Inc. Primary endpoints: Dose Limiting Toxicity at 4 weeks and Adverse Events at 90 days. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
AK150
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT07566247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07566247.